|
Dec 21
|
M&A market: What will it look like in 2024?
|
|
Dec 11
|
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
|
|
Dec 6
|
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
|
|
Dec 1
|
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
|
|
Nov 30
|
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
|
|
Sep 12
|
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
|
|
Sep 7
|
Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?
|
|
Sep 6
|
Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
|
|
Apr 29
|
16% of this Seagen Inc. (NASDAQ:SGEN) insider's holdings were sold in the last year
|
|
Apr 27
|
Seattle Genetics (SGEN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Apr 27
|
Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
|
|
Apr 27
|
Seagen Reports First Quarter 2023 Financial Results
|